A proposed oral treatment for Type 1 diabetes in adults has been rejected in the U.S.
The rejection of what would have been the first oral treatment for Type 1 diabetes in the U.S. is a big setback for Lexicon Pharmaceuticals Inc.
, a small company based in a Houston suburb that currently has one product on the market and losses of nearly $1.5 billion as of Dec. 31. Lexicon is developing the treatment, which is called Zynquista, with French pharmaceutical giant Sanofi.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
FDA rejects Sanofi-Lexicon add-on pill for type 1 diabetesThe U.S. Food and Drug Administration declined to approve a drug developed by Sa...
Weiterlesen »
FDA approves the first drug designed to treat postpartum depressionThe FDA approved the first drug specifically for postpartum depression, a debilitating condition that affects about 400,000 women a year in the United States.
Weiterlesen »
FDA says cybersecurity vulnerabilities found in some Medtronic devicesThe U.S. Food and Drug Administration (FDA) on Thursday said cybersecurity vulne...
Weiterlesen »
Indonesian airline Garuda is canceling its $6 billion order for 49 Boeing 737 Max jetsBoeing 737 Max planes have been grounded by authorities after two recent fatal crashes.
Weiterlesen »
FDA approves first treatment for postpartum depressionThe FDA has approved a new medication called Zulresso, a completely new class of drug designed specifically to treat postpartum depression. It’s a one-time infusion given in a hospital over two and a half days.
Weiterlesen »
FDA issues warning to two breast implant makers over safety concernsLess than a week before a major hearing on breast implant safety, the FDA issued two warning letters to implant manufacturers, citing their failure to do proper safety studies.
Weiterlesen »
Sage Therapeutics’ Drug for Postpartum Depression Gets FDA NodU.S. health regulators on Tuesday approved Sage Therapeutics Inc.’s Zulresso, the first medication specifically intended for women with postpartum depression.
Weiterlesen »